Premium
Benzodiazepine, psychotropic medication, and dementia: A population‐based cohort study
Author(s) -
Shash Dalia,
Kurth Tobias,
Bertrand Marion,
Dufouil Carole,
BarbergerGateau Pascale,
Berr Claudine,
Ritchie Karen,
Dartigues JeanFrancois,
Bégaud Bernard,
Alpérovitch Annick,
Tzourio Christophe
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.10.006
Subject(s) - dementia , hazard ratio , benzodiazepine , medicine , prospective cohort study , cohort , confidence interval , cohort study , population , psychiatry , disease , environmental health , receptor
Benzodiazepine use has been associated with increased risk of dementia. However, it remains unclear whether the risk relates to short or long half‐life benzodiazepines and whether it extends to other psychotropic drugs. Methods Prospective cohort study among 8240 individuals ≥65, interviewed on medication use. Incident dementia confirmed by an end point committee after a multistep procedure. Results During a mean of 8 years of follow‐up, 830 incident dementia cases were observed. Users of benzodiazepines at baseline had a 10% increased risk of dementia (adjusted hazard ratio [HR], 1.10; 95% confidence interval, 0.90–1.34). However, long half‐life (>20 hours) benzodiazepine users had a marked increased risk of dementia (HR = 1.62; 1.11–2.37) compared with short half‐life users (HR = 1.05; 0.85–1.30). Users of psychotropics had an increased risk of dementia (HR = 1.47; 1.16–1.86). Discussion Results of this large, prospective study show increased risk of dementia for long half‐life benzodiazepine and psychotropic use.